Table 1.

Overview of clinical trials and approved drugs targeting transient receptor potential vanilloid (TRPV)1–4.

Drug/Agent	TRPV Modulation	Disease	Clinical Stage	References
Capsaicin 8% topical patch (Qutenza®)	TRPV1 agonist	Neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy of the feet	Approved in 2009	[26]
Capsaicin (Intra-articular injection)	TRPV1 agonist	Osteoarthritic pain	Phase II	[31]
Resiniferatoxin	TRPV1 agonist	Osteoarthritic pain	Phase III	[32]
NEO6860	TRPV1 antagonist	Osteoarthritic pain	Phase II	[27]
AZD1386	TRPV1 antagonist	Gastroesophageal reflux disease	Phase II	[33]
AMG-517	TRPV1 antagonist	Osteoarthritic pain	Phase II	[28]
SB705498	TRPV1 antagonist	Non-allergic rhinitis	Phase II	[34]
Mavatrep	TRPV1 antagonist	Osteoarthritic pain	Phase I	[30]
MK-2295	TRPV1 antagonist	Postoperative dental pain	Phase II	[35]
DWP05195	TRPV1 antagonist	Postoperative dental pain	Phase II	[36]
GRC15300	TRPV3 antagonist	Neuropathic pain	Phase II	[29]
GSK2798745	TRPV4 antagonist	Pulmonary edema, congestive heart failure	Phase II	[37,38]